TY - JOUR
T1 - Investigation of copper-cysteamine nanoparticles as a new photosensitizer for anti-hepatocellular carcinoma
AU - Huang, Xuejing
AU - Wan, Fengjie
AU - Ma, Lun
AU - Phan, Jonathan B.
AU - Lim, Rebecca Xueyi
AU - Li, Cuiping
AU - Chen, Jiagui
AU - Deng, Jinghuan
AU - Li, Yasi
AU - Chen, Wei
AU - He, Min
N1 - Publisher Copyright:
© 2019, © 2019 Taylor & Francis Group, LLC.
PY - 2019/6/3
Y1 - 2019/6/3
N2 - Hepatocellular carcinoma (HCC) is a primary malignancy of the liver and occurs predominantly in patients with underlying chronic liver disease and cirrhosis. HCC is now the third leading cause of cancer deaths worldwide, with over 500,000 people affected. However, there is no complete effective (ideal) treatment for liver cancer yet, and the new methods are expected to be discovered. Herein, for the first time, we report the anti-HCC effects of copper-cysteamine nanoparticles (Cu-Cy NPs), a new type of photosensitizers. An in vitro 3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay shows that Cu-Cy NPs could significantly reduce the activity of HepG2 cells at a very low dose after a short time of ultraviolet radiation. In addition, we found that cell death was induced by Cu-Cy NPs, which is associated with cellular apoptosis. This implied that apoptosis might be the main mechanism of the Cu-Cy’s anti-HCC activity. Furthermore, we found that Cu-Cy NPs obviously inhibited the tumor growth in vivo. More interestingly, we found that the soluble Cu-Cy NPs were able to enter exosomes which were secreted by tumor cells, and exosomes could be used to deliver Cu-Cy NPs to target tumor cells. All these observations suggest that Cu-Cy NPs have a good potential for cancer treatment.
AB - Hepatocellular carcinoma (HCC) is a primary malignancy of the liver and occurs predominantly in patients with underlying chronic liver disease and cirrhosis. HCC is now the third leading cause of cancer deaths worldwide, with over 500,000 people affected. However, there is no complete effective (ideal) treatment for liver cancer yet, and the new methods are expected to be discovered. Herein, for the first time, we report the anti-HCC effects of copper-cysteamine nanoparticles (Cu-Cy NPs), a new type of photosensitizers. An in vitro 3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay shows that Cu-Cy NPs could significantly reduce the activity of HepG2 cells at a very low dose after a short time of ultraviolet radiation. In addition, we found that cell death was induced by Cu-Cy NPs, which is associated with cellular apoptosis. This implied that apoptosis might be the main mechanism of the Cu-Cy’s anti-HCC activity. Furthermore, we found that Cu-Cy NPs obviously inhibited the tumor growth in vivo. More interestingly, we found that the soluble Cu-Cy NPs were able to enter exosomes which were secreted by tumor cells, and exosomes could be used to deliver Cu-Cy NPs to target tumor cells. All these observations suggest that Cu-Cy NPs have a good potential for cancer treatment.
KW - copper-cysteamine
KW - Hepatocellular carcinoma
KW - nanoparticles
KW - photodynamic therapy
KW - photosensitizer
UR - http://www.scopus.com/inward/record.url?scp=85061340050&partnerID=8YFLogxK
U2 - 10.1080/15384047.2018.1564568
DO - 10.1080/15384047.2018.1564568
M3 - Article
C2 - 30727796
AN - SCOPUS:85061340050
SN - 1538-4047
VL - 20
SP - 812
EP - 825
JO - Cancer Biology and Therapy
JF - Cancer Biology and Therapy
IS - 6
ER -